New myeloma treatment study for transplant-ineligible patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new medicine (HLX15-IV) compared to the standard treatment DARZALEX, both given with lenalidomide and dexamethasone (Rd). It is for people newly diagnosed with multiple myeloma who are not able to have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with multiple myeloma (a type of blood cancer) and have never been treated for it.
- You should not be eligible for or planning to have a stem cell transplant.
- You must be fully active and able to do all your usual activities without help (ECOG score 0).
- You cannot have certain other plasma cell conditions like amyloidosis or smoldering myeloma.
- You must not have had any other cancer in the last 3 years, except for some skin cancers.
- You should not have severe asthma, COPD, or heart problems that are not well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for newly diagnosed multiple myeloma in patients who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control myeloma and improve survival.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.